ABL1 and neoplasm: In addition, Dasa only was also similarly administered and exhibited potent tumor growth inhibition in vivo without significant loss of body weight and failed to reduce protein levels of BCR–ABL, as reported in previous studies (26) (Fig. 6, H–N).